Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04615078
Other study ID # ALMED-20-001
Secondary ID 2020-A02150-39
Status Completed
Phase N/A
First received
Last updated
Start date January 18, 2021
Est. completion date July 25, 2022

Study information

Verified date June 2023
Source Air Liquide Santé International
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ETAPES Program, a French national Experimentation in Telemedicine for the Improvement of Healthcare Pathways, was launched in 2018 for 4 years. Its objectives were to provide a temporary public reimbursement for medical telemonitoring in order to determine the benefits for the patient and the impact on medical organization and healthcare costs. In particular, this program applies to patients suffering from hypercapnic chronic respiratory failure and requiring home non invasive ventilation (NIV). For these patients, the ETAPES program combines NIV telemonitoring and therapeutic education. e-VENT study aims at evaluating the ETAPES program, implemented using the Chronic Care Connect™ telemonitoring solution, versus Standard of Care, on the effectiveness of home NIV, measured by average PtCO2, reflecting the level of nocturnal alveolar hypoventilation.


Description:

A prospective randomized study with two arms. The primary endpoint is the level of nocturnal alveolar hypoventilation, defined as the average PtCO2 in nocturnal capnography performed at 6th month. Patients with hypercapnic chronic respiratory failure requiring home NIV (n=100). Multi-center study conducted in France involving approximately 20 sites Product under study: Chronic Care Connect Pneumology telemonitoring solution, combining: - a technical solution for the transmission and analysis of ventilator data, with the generation of alerts by a CE-marked algorithm; - an organizational solution relying on a nurse call center. Study design: - First visit: eligibility criteria confirmation; randomization to 2 groups: - the "Telemonitoring" group will participate in the ETAPES experimentation, with remote monitoring of their ventilator data with generation of alerts to the nurse call center, medical action if requested, and therapeutic education. - the "Standard of Care" group will receive standard medical follow-up, with transmission of their ventilator data without generation of alerts. - Second visit (6th month): arterial blood gases, nocturnal capnography. Collection of medical events having occurred in the past 6 months. - Third visit (12th month): for COPD patients only - Collection of medical events having occurred in the past 6 months. - At the end of the study, the investigators will complete a qualitative questionnaire on their telemonitoring practice.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date July 25, 2022
Est. primary completion date July 25, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with chronic respiratory failure for whom treatment with home NIV was prescribed at inclusion or two months earlier, and whose service provider is ADEP Assistance, ADAIR Assistance, ARAIR Assistance or VitalAire, - Patient who meets all eligibility criteria to participate in the ETAPES program, namely: - Patient aged 18 and over; - Patient receiving NIV as part of an indication recognized by the Société de Pneumologie de Langue Française and the Haute Autorité de Santé; - Patient never before included in the ETAPES program for the remote medical monitoring of their chronic respiratory failure; - Patient having agreed to participate in the ETAPES program with the Chronic Care Connect Pneumology solution operated by the service providers ADEP Assistance, ADAIR Assistance, ARAIR Assistance or VitalAire, in the event that they are randomized to the Remote Medical Monitoring group; - Patient agreeing to the collection of data from their ventilator via remote transmission; - Patient fitted with a ventilator compatible with the Chronic Care Connect Pneumology solution; - Patient with health insurance cover; - Patient who has signed the consent form for the study. Exclusion Criteria: - Patient who has any of the non-eligibility criteria for the ETAPES program: - Physical or mental inability to use all components of the remote medical monitoring project, as determined by the doctor wishing to include the patient in the remote medical monitoring project; - Patient with cancer with a life expectancy of less than 12 months estimated by the pulmonologist; - Patient with more than three COPD respiratory decompensations resulting in hospitalization within the previous 12 months; - Patient with diagnosed neuromuscular disease; - Estimated poor compliance or standard adherence to treatment according to the physician including the patient; - Patient's refusal of treatment support; - No permanent place of residence; - Patient participating in another intervention research program.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ETAPES Program
The Chronic Care Connect Pneumology is a remote medical monitoring solution, combining: A technical solution for the transmission and analysis of ventilator data, leading to alerts generated by an algorithm ; An organizational solution relying on a nurse call center.

Locations

Country Name City State
France Centre Hospitalier de Boulogne sur Mer Boulogne-sur-Mer
France Centre Hospitalier de Bligny Briis-sous-Forges
France Claude SCHMITZ, MD Colmar
France Hôpital Forcilles - Fondation Cognacq-Jay Férolles-Attilly
France François BUGHIN, MD - Clinique du Millénaire Montpellier
France Clinique FSEF Paris 16ème Paris
France Groupe Hospitalier Pitié Salpêtrière-Charles Foix Paris
France Groupe Médical de Pneumologie, Polyclinique Saint Laurent Rennes
France Centre Hospitalier Universitaire de Toulouse - Hôpital Larrey Toulouse
France Centre Hospitalier Universitaire de Tours - Hôpital Bretonneau Tours
France Pierre-Henri GUILLAUD, MD Vienne

Sponsors (1)

Lead Sponsor Collaborator
Air Liquide Santé International

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Nocturnal alveolar hypoventilation data Average PtCO2, measured by transcutaneous capnography 6th month
Secondary Number of medical events (consultations, hospitalizations and COPD exacerbations) related to Chronic Respiratory Failure Average number of medical events (consultations, hospitalizations and COPD exacerbations) related to Chronic Respiratory Failure per patient 6th month; 12th month
Secondary Measurement of diurnal PaO2 and PaCO2 Measurement of diurnal PaO2 and PaCO2 (mmHg) without NIV, in stable state at rest 6th month
Secondary S3-NIV questionnaire Questionnaire evaluating sleep, side effects and symptoms in patients on home NIV, each time the service provider visits the patient at home Through study completion, an average estimated at around 7 months
Secondary DIRECT questionnaire Total health-related quality-of-life score from the DIRECT questionnaire as recommended in the ETAPES program, submitted to the patients in the month following their inclusion and in the 6th month 1st month; 6th month
Secondary Quality of NIV treatment Daily data teletransmitted by ventilators throughout the follow-up period Through study completion, an average estimated at around 7 months
Secondary Patient satisfaction questionnaire about Telemonitoring services Questionnaire developed for the study to collect patient satisfaction about the educational component of the telemonitoring service at the end of their participation to the study 6th month
See also
  Status Clinical Trial Phase
Completed NCT03282019 - Study of Long-term HFNC for COPD Patients With HOT N/A
Completed NCT05573464 - A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease Phase 3
Recruiting NCT06040086 - Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Phase 3
Not yet recruiting NCT06376994 - Multi-Center Clean Air Randomized Controlled Trial in COPD Phase 3
Completed NCT02728674 - Management of Patients With Respiratory Symptoms in Sweden N/A
Completed NCT02926534 - Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan N/A
Completed NCT02797392 - Feasibility of a Preventive Program Against Lifestyle Related Diseases N/A
Recruiting NCT02415478 - Bronchioscopic Lung Volume Reduction (BLVR) N/A
Completed NCT02512510 - Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03487406 - Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2) Phase 2
Completed NCT02459080 - Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT02774226 - Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02518139 - A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT01893476 - A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management N/A
Withdrawn NCT01908933 - Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema Phase 3
Completed NCT01908140 - Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT01701869 - Microbiology & Immunology of the Chronically-inflamed Airway N/A
Recruiting NCT02527486 - Seoul National University Airway Registry N/A
Withdrawn NCT01377428 - Efficacy of Indacaterol 150 µg Versus Formoterol Phase 4